News and Announcements
OncoSil Medical Appoints Charles Rowland as President
- Published December 15, 2015 1:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th December 2015, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce the appointment of Mr. Charles Rowland as President, OncoSil Medical USA.
Mr. Rowland was previously President of Sirtex Medical US from 2002 to 2006, and is a highly experienced healthcare executive with a successful record of commercialising medical devices and growing medical device companies in the diagnostics, cardiac patient management and liver cancer markets.
In his role with OncoSil Medical Mr. Rowland will be responsible for developing and executing the Company’s US Business plan and will be the Company’s official representative with the US FDA as it works towards US licensure for its lead product candidate, the OncoSilTM localiased radiation treatment for cancer.
To read the full announcement, please click here.